Intravitreal Anti–Vascular Endothelial Growth Factor for Submacular Hemorrhage from Choroidal Neovascularization – Corrected Proof
Purpose: To evaluate the efficacy of intravitreal anti–vascular endothelial growth factor (VEGF) monotherapy for patients diagnosed with exudative age-related macular degeneration (AMD) accompanied by submacular hemorrhage.Design: Retrospective, observational case series.Participants: Ninety-one eyes of 91 patients who initially presented with submacular hemorrhage associated with exudative AMD from October 2009 to September 2012. Patients were followed up for at least 6 months after treatment.Methods: Best-corrected visual acuity (BCVA) was measured at diagnosis and at 1, 3, and 6 months after treatment. The duration of symptoms was estimated. The extent of hemorrhage was estimated using fundus photography, and central foveal thickness was measured (Read more...)